LRRK2 and respiratory tract infectious disorder: This outcome suggested to us that this model employs a challenge dosage within a responsive range that is sensitive to change and thus suitable for detecting/assessing genotypic effects of either Lrrk2 or Snca mutants, similar to those that were observed in the nasally-inoculated, respiratory infection model, where a much higher dosage was employed (1.7x105 PFU/mouse, to achieve a 50% lethality) [4,10].